Contact
    Start Publications Biosensing Tacrolimus in Human Whole Blood by Using a Drug ...
    ←  Publication Finder
    QSense

    Biosensing Tacrolimus in Human Whole Blood by Using a Drug Receptor Fused to the Emerald Green Fluorescent Protein

    Year: 2022

    Journal: Anal. Chem., Volume 94, NOV 29, page 16337–16344

    Authors: Benito-Pena, Elena; Moreno-Bondi, Maria C.; Glahn-Martinez, Bettina; Lucchesi, Giacomo; Pradanas-Gonzalez, Fernando; Manzano, Ana Isabel; Canales, Angeles; Caminati, Gabriella

    Organizations: Spanish Ministry of Science and Innovation (MICINN); Universidad Com-plutense de Madrid (UCM); [RTI2018-096410 B-C21]; [PDI2021-127457OB-C21]

    Tacrolimus (FK506) is an immunosuppressant drug (ISD) used to prevent organ rejection after transplantation that exhibits a narrow therapeutic window and is subject to wide inter-and intra-individual pharmacokinetic fluctuations requiring careful monitoring. The immunosuppressive capacity of FK506 arises from the formation of a complex with immunophilin FKBP1A. This paper describes the use of FKBP1A as an alternative to common antibodies for biosensing purposes. Bioassays use recombinant FKBP1A fused to the emerald green fluorescent protein (FKBP1A-EmGFP). Samples containing the immunosuppressant are incubated with the recombinant protein, and free FKBP1A- EmGFP is captured by magnetic beads functionalized with FK506 to generate a fluorescence signal. Recombinant receptor-drug interaction is evaluated by using a quartz crystal microbalance and nuclear magnetic resonance. The limit of detection (3 ng mL-1) and dynamic range thus obtained (5-70 ng mL-1) fulfill therapeutic requirements. The assay is selective for other ISD usually coadministered with FK506 and allows the drug to be determined in human whole blood samples from organ transplant patients with results comparing favorably with those of an external laboratory.
    View publication